In the latest edition from our Clinical Trials Special Report Series, we break down China’s clinical trials landscape and analyze the government investments and reforms that are making the country more attractive for inclusion in global drug development programs of pharma companies of all sizes. This comprehensive analysis will also discuss further initiatives needed to make China a major player in the drug development arena. Key features include: Government initiatives driving growth; Benefit analysis for domestic and global pharma; Big Pharma plans for the region; Drug development pipeline; Select list of 100+ CROs; Charts and figures. Recommended for: Biotech and pharmaceutical companies seeking information on growth and challenges in China’s clinical trials market; Investment firms covering the life sciences industry in emerging markets; CROs conducting business in China.